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Abstract
Background: Mounting evidence indicates that inflammatory mechanisms drive systemic sclerosis (SSc)
vasculopathy and fibrosis, especially early in the disease. Therefore, patients with very early SSc could benefit from
early treatments targeting inflammation. Glucocorticoids are among the most potent anti-inflammatory and
immunosuppressive agents. Several studies have demonstrated a mixed response to treatment with glucocorticoids
in SSc, probably because it is seldom initiated at very early stages of the disease. We hypothesise that by inhibiting
the inflammatory process driving SSc disease progression, glucocorticoid treatments will induce remission in
patients with very early SSc.
Methods/design: This study is a 12-week, randomised, double-blind, placebo-controlled trial analysing the effects
of high-dose intravenous methylprednisolone in very early SSc. Thirty patients who fulfil the criteria for very early
SSc will be randomly assigned in a 2:1 ratio to receive either intravenous methylprednisolone or a placebo on three
consecutive days over three consecutive months. In this study, the primary endpoint will be the change in capillary
density between the baseline and after 12 weeks of treatment. The secondary outcomes of this study are a change
in selected biomarkers, other changes in the nailfold capillaries, signs of established SSc and changes in physical
function, general health and utilities, as reported through questionnaires.
Discussion: This trial is the first aiming to treat very early SSc and is promising because it targets the very early
stages of the disease process by using an inexpensive and relatively safe treatment known to be highly effective
against inflammation. The use of vasculopathy and inflammatory biomarkers as well as clinical signs and symptoms
as the endpoints in our study enables us to meet the patient need for markers of disease activity. If it is possible to
prevent clinically significant disease in patients with very early SSc by using a safe treatment, this will cause a
paradigm shift in scleroderma care and research.
Trial registration: ClinicalTrials.gov Identifier: NCT03059979. Registered on 20 February 2017.
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Background
In systemic sclerosis (SSc), the extent of organ involve-
ment largely determines patient quality of life and dis-
ease burden. Organ involvement often occurs in the first
three years of the disease and is tightly linked to an in-
crease in mortality, decreasing the 5-year survival rate to
84% to 91%. To date, no treatment is available to cure
SSc and its aetiology is unknown [1]. The major patho-
genic features of SSc are a dysregulation of the immune
system, dysfunction of the vasculature, and the activa-
tion of fibroblasts and other resident cells. Several stud-
ies have indicated that inflammatory mechanisms drive
SSc vasculopathy and fibrosis, especially at the early
stages of the disease [2–7].
In addition, it is likely that SSc shares an autoimmune
inflammatory basis with other systemic autoimmune dis-
eases such as lupus nephritis [8]. Glucocorticoids, some of
the most potent anti-inflammatory and immunosuppres-
sive agents, can induce remission in systemic autoimmune
diseases, including lupus nephritis and dermatomyositis,
and have an immediate and profound effect on the traf-
ficking of leucocytes [9–11]. Furthermore, glucocorticoids
affect both T- and B-lymphocytes.
A systematic review on the use of glucocorticoids in
treating SSc showed conflicting results in skin and lung
involvement but positive effects on myopathy [12]. The
partially poor clinical response to glucocorticoid treat-
ment in SSc might result from delays in its application,
meaning that it cannot prevent the very early induction
of vasculopathy and fibrosis arising as a result of inflam-
mation [1, 13–15].
The European League Against Rheumatism (EULAR)
Scleroderma Trials and Research Group has identified
preliminary criteria for the very early diagnosis of systemic
sclerosis (VEDOSS), which include the combination of
Raynaud’s phenomenon, disease-specific auto-antibodies,
typical nailfold capillaroscopic findings and “puffy fingers”
[16, 17].
Recent developments in our understanding of the over-
lapping disease mechanisms of SSc and other auto-
immune diseases, the inflammatory mechanisms involved
in early SSc and the partial response of SSc treated with
glucocorticoids suggest a possible treatment opportunity
in patients with early SSc. The aim of this trial is to exam-
ine the effects of high-dose glucocorticoids on the inhib-
ition of the inflammatory process in very early SSc.
Methods/design
This 12-week, double-blind, randomised, placebo-controlled
trial is under way (inclusion began on January 1, 2017, and
is open until July 1, 2018) at the Department of Rheumatol-
ogy of Radboud University Medical Centre in Nijmegen,
The Netherlands.
Objectives
The aim of this study is to analyse whether high-dose
methylprednisolone has an effect on very early SSc in terms
of nailfold capillaromicroscopy (NCM) abnormalities, SSc
signs and symptoms, and inflammation biomarkers. This
led to the following research questions.
Primary objective
The purpose of this study was to determine the effect of
short-term treatment with high-dose glucocorticoids on
vasculopathic abnormalities, as measured by using NCM
in patients with very early SSc.
Secondary objectives
The key secondary objective is to determine the effects
of the short-term treatment of SSc with high-dose gluco-
corticoids on changes in the following:
 the signs and symptoms of disease progression,
 inflammation biomarkers, and
 general health and utilities, as measured by
standardised questionnaires.
Study design rationale
In order to investigate the effect of high-dose methylpred-
nisolone in very early SSc, we have designed a randomised,
placebo-controlled, double-blind, mono-centre superiority
trial with a primary endpoint of changes in nailfold capillary
density after 12 weeks. Randomisation will be performed in
blocks of six after the stratification of anti-centromere/
anti-topoisomerase auto-antibodies, sex and age and there
will be a 2:1 patient allocation to groups receiving intraven-
ous methylprednisolone or placebo.
Study outcome rationale
In SSc, the outcome measures of interventions are not
extensively available. The most accepted outcome meas-
ure is a change in skin involvement, measured by using
the modified Rodnan skin score (mRSS). However, in
our study population of patients with very early SSc, the
mRSS is 0 by definition at the outset. Nailfold capillary
abnormalities have been identified as a symptom for
diagnosing early SSc and are included in the American
College of Rheumatology/EULAR (ACR/EULAR) classi-
fication criteria for SSc. Nailfold capillary abnormalities
are evaluated by using NCM. The typical changes of the
nailfold capillaries during SSc consist of the appearance
of the following capillaroscopic hallmarks: the presence
of enlarged or giant capillaries, haemorrhages, loss of ca-
pillaries, disorganisation of the microvascular array, and
capillary ramifications. Semi-qualitative rating scores, es-
pecially of capillary density, have value in predicting the
occurrence of organ involvement and mortality in SSc
[18]. To date, the effect of immunosuppressant drugs on
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the nailfold capillaries in SSc has not been extensively stud-
ied. The most successful treatment of progressive SSc to
date involved an autologous haematopoietic stem cell trans-
plantation (ASCT), after which microcirculation estimated
by using NCM was reported to be improved in separate
studies [19, 20]. In patients who received ASCT, an im-
proved capillary density was observed just 3 months after
treatment and persisted during follow-ups over 24 months
while no NCM modification was detected in patients who
received cyclophosphamide [20]. In early SSc, the presence
of giant capillaries is the dominant NCM feature, which
can entail a decreased capillary density [21].
Participants, intervention and outcomes
Inclusion criteria
Patients who meet the following criteria at randomisa-
tion are eligible for the study:
1. age of more than 18 years,
2. fulfil VEDOSS criteria [16]: Raynaud’s phenomenon
AND positive test for anti-centromere or anti-
topoisomerase antibodies AND nailfold capillaro-
scopic findings typical of SSc,
3. puffy fingers for less than 3 years, and
4. mRSS of 0.
Exclusion criteria
Patients who, at randomisation, meet any of the follow-
ing criteria are not eligible for the study:
1. presence of acrosclerosis, acro-osteolysis or digital
ulcers,
2. presence of anti-RNA polymerase III auto-antibodies,
3. previous systemic treatment for SSc, namely
methotrexate, prednisone (>14 days in the previous
6 months), mycophenolate mofetyl or
cyclophosphamide,
4. clinically significant internal organ involvement:
diffusing capacity for carbon monoxide (DLCO) less
than 80% predicted, vital capacity less than 70%
predicted, renal dysfunction with glomerular
filtration rate less than 60 mL/min, diastolic
dysfunction more than grade 1 on
echocardiography, pulmonary hypertension, or
weight loss more than 10% in the last 6 months
with unknown cause, and
5. contra-indications for methylprednisolone.
Intervention
Investigational product/treatment
Eligible patients will be randomly assigned to groups, receiv-
ing either a daily infusion of methylprednisolone (1000 mg)
or a placebo (physiologic salt solution identical in appear-
ance) on three consecutive days in three consecutive
months. The study drug and placebo will be provided by the
local hospital pharmacy. Infusions will be given at the out-
patient facilities of the rheumatology department.
Use of co-medication
All patients will receive prophylactic therapy with an
angiotensin-converting enzyme inhibitor and a proton-pump
inhibitor for the duration of the study. Treatment with other
systemic therapies for SSc symptoms will be avoided when-
ever possible during the study and will be regarded as a
protocol violation.
Follow-up treatment
After the 12-week assessment, patients will usually re-
ceive no treatment, as is the standard care in very early
SSc. However, methotrexate (25 mg per week) can be
started if a patient develops limited skin involvement but
no significant internal organ involvement. Intravenous
pulses of cyclophosphamide or mycophenolate mofetil
can be started if a patient has rapidly evolving skin
involvement or if signs of significant internal organ
involvement are present or if both occur.
Escape treatment
In case of the significant worsening of symptoms (devel-
opment of diffuse skin involvement, weight loss of more
than 10%, or the occurrence of significant internal organ
involvement), the treatment with methylprednisolone
will be stopped and an appropriate treatment will be
started in accordance with the EULAR treatment recom-
mendations for SSc [22].
Outcome measures
Primary outcome
In this study, the primary endpoint will be the change in
capillary density between the baseline and after 12 weeks
of treatment.
Secondary outcomes
The secondary outcomes (all compared between the
baseline and week 12 or between the baseline and 1
year) of this study are (a change in):
 selected biomarkers: the interferon signature in
peripheral blood cells, CXCL4, interleukin-1 beta
(IL-1β), IL-6, tumor necrosis factor-alpha (TNF-α),
ET-1, intercellular adhesion molecule 1 (ICAM-1)
and vascular endothelial growth factor (VEGF)
[3, 23–27];
 nailfold capillary changes other than capillary
density and the presence of giant capillaries
 an mRSS; the presence of puffy fingers; the presence of
synovitis; the presence of tendon friction rubs; fulfilling
EULAR/ACR classification criteria for SSc [28];
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 pulmonary function tests; the presence of interstitial
lung disease; a suspicion of pulmonary hypertension; and
 physical function, general health and utilities as
measured by the Scleroderma Health Assessment
Questionnaire (SHAQ), 36-Item Short Form Health
Survey (SF-36), EuroQOL five dimensions questionnaire
(EQ5D) and Gastrointestinal Tract Questionnaire (GIT).
Assessments
Regular visits are planned at the baseline and after
months 1, 2, 3, 6, 9 and 12. See Fig. 1—according to the
Additional file 1: SPIRIT (Standard Protocol Items: Rec-
ommendations for Interventional Trials) checklist—for
an overview of all visits and assessments.
Sample size
The effect of high-dose methylprednisolone on nailfold capil-
lary changes and other outcomes in early SSc is unknown;
therefore, the optimal size of a pilot trial is unknown. If the
sample is too small, the estimate of the effect will be too un-
certain. If the sample is too large, it may be judged as un-
necessarily exposing participants to risks and burdens and
therefore as being unethical. Furthermore, setting the sample
size too high may lead to a preventable failure to reach the
recruitment target. To minimise the risk for participants and
maximise the information gained, we judged that the inclu-
sion of 30 patients (20 in the treatment arm and 10 in the
placebo arm) would be appropriate for this pilot study.
When adopting the usual alpha of 0.05, power of 0.80, stand-
ard deviation of 0.9 and randomisation scheme of 2:1, a
between-group difference of nearly 1.0 in the capillary dens-
ity score thus would represent a statistically significant differ-
ence, using the standard sample size formula. In previous
ASCT treatments for SSc, the change in capillary density
over the first 12 weeks was 1.5 in the intervention group,
and there was no change in the control group [20]. Patients
are randomly assigned at a 2:1 ratio to maximise the infor-
mation about the experimental intervention, which can be
STUDY PERIOD
Enrolment Allocation Post-allocation
Month -0.5 0 1 2 3 6 9 12
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Drug intervention
ASSESSMENTS:
Physical 
examination
X
EULAR/ACR 
criteria
Laboratory 
assessments
X
Plasma biomarkers
Nailfold 
capillaroscopy
Pulmonary 
function tests
X X X
HRCT chest 
X X
Echocardiography
X X
Skin biopsy
X X X
Adverse events
Concomitant 
medication
Questionnaires
X X X
Fig. 1 Study visits and procedures. Pulmonary function tests consisting of vital capacity, total lung capacity and carbon monoxide (CO) diffusion
capacity. Plasma biomarkers consist of CXCL4, interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNFα), IL-6, ET-1, intercellular adhesion
molecule 1 (ICAM-1) and vascular endothelial growth factor (VEGF). Abbreviation: HRCT high-resolution computer tomography
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justified as the risks of the intervention are known and rela-
tively low.
Randomisation, concealment and blinding
Patients are randomly assigned in a 2:1 fashion to intraven-
ous methylprednisolone or placebo in blocks of six, following
stratification by either anti-centromere or anti-topoisomerase
auto-antibodies, sex and age. Patients will be randomly
assigned by using Castor, an online data collection tool for
medical research. Randomisation will result in the allocation
of a unique number to each patient. Physical examinations
for efficacy outcomes are performed by a researcher who is
blind to the occurrence of both mild and serious adverse
events. The physicians who accompany the intervention and
perform assessments for vital status and adverse events do
not assess the efficacy outcomes. To maintain the overall
quality and legitimacy of the clinical trial, the randomisation
code can be broken only when knowledge of the actual treat-
ment is absolutely necessary for further management of the
patient or at the request of the safety monitoring committee.
Statistical analysis
The data will be analysed primarily according to the
intention-to-treat principle. Missing values due to par-
ticipant drop-out are treated according to the last obser-
vation carried forward. A P value of 0.05 will be used to
denote statistical significance for between-group differ-
ences in the primary outcome.
Between-group differences in the change in efficacy out-
come variables between the baseline and week 12 will be
analysed by using an analysis of covariance or logistical re-
gression. Similarly, the ongoing changes to the continuous
outcomes will be analysed between the baseline and weeks 4,
8 and 12 by using a repeated-measures analysis of variance.
Serious and minor adverse events will be tabulated by
group, and depending on the occurrence, a time-to-event
analysis may be used to analyse between-group differences
in serious adverse events. The use of any immunosuppres-
sive therapy between week 12 and the 1-year follow-up will
be described for each of the two groups.
Ethics and dissemination
The study has received ethical review board approval
(number 2015–004613-24). Data on the recruitment, effi-
cacy, safety, protocol updates and all aspects concerning
good clinical practice are reviewed by the data safety mon-
itoring board, which consists of an internal medicine
physician, a pharmacist and an epidemiologist.
Discussion
In designing this research protocol, we needed to address a
number of clinical and methodological issues. First, patients
who are still in the inflammatory phase of the disease are
more likely to respond to treatment with glucocorticoids;
therefore, the choice was made to include only patients
who fulfil the VEDOSS criteria, but not the 2013 ACR/
EULAR classification criteria, for SSc [28].
Second, treatment consisting of short pulses of methyl-
prednisolone is often better tolerated than continuous high
oral doses, while fewer long-term consequences are seen
when using short methylprednisolone pulses. The choice of
an intravenous infusion of high-dose (1000 mg) methyl-
prednisolone was based on the treatment regimens in other
auto-immune diseases, such as lupus nephritis and derm-
atomyositis, in cases of exacerbation or failing standard
therapy or both [9, 10]. In these diseases, high-dose methyl-
prednisolone has been shown to induce remission. The
schedule of three consecutive days of treatment during
three consecutive months was chosen because this method
is generally used in severe autoimmune diseases.
Disease activity in SSc is measured mostly by mRSS and,
in cases with pulmonary involvement, by pulmonary func-
tion results. However, to date, no biomarkers are available
to follow-up the disease activity. The use of vasculopathy
and inflammatory biomarkers, as well as clinical signs and
symptoms, as endpoints in our study, enables us to meet
the patient need for alternative markers on disease activity,
as the known signs and symptoms of worsening prognosis
are present in only a minority of patients.
This trial is the first to aim to treat very early SSc and is
promising because it targets the early stages in the disease
process using a relatively safe and inexpensive treatment
known to be highly effective against inflammation. If it is
possible to prevent significant clinical disease in patients
with very early SSc by using a safe treatment, this will cause
a paradigm shift in scleroderma care and research. The
knowledge gained from this project will facilitate further re-
search into the efficacy and safety of using high-dose gluco-
corticoids in SSc treatment and enable this treatment to
progress through a pivotal phase III trial. We anticipate
that, if successful, this project will enormously increase re-
search efforts into the early treatment of SSc and decrease
the cost of health care for these patients.
In this trial, patients with SSc receive treatment very early
in the progression of their disease, which could change the
long-term outcome of SSc. In current daily practice, pa-
tients so early in the disease course do not receive treat-
ment, although they can be at risk for early escalation and
internal organ involvement, reducing their prognosis. A
trial to investigate the efficacy of treatment using high-dose
glucocorticoids will provide us with the opportunity to
change this disease course, reducing the disease burden of
a portion of patients with SSc. If the treatment of very early
SSc with high-dose glucocorticoids is effective, this will
prelude a pivotal change in the treatment of SSc.
Trial status
Open for inclusion.
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Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOC 121 kb)
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